# The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis

> **NCT01867645** · PHASE1 · TERMINATED · sponsor: **Medical University of Vienna** · enrollment: 38 (actual)

## Conditions studied

- Polyneuropathies

## Interventions

- **DRUG:** IgM-enriched Intravenous Immunoglobulins
- **DRUG:** Human Albumin

## Key facts

- **NCT ID:** NCT01867645
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-12
- **Primary completion:** 2009-04
- **Final completion:** 2011-04
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** The trial was terminated early due to futility in reaching the primary endpoint.
- **Last updated:** 2013-06-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01867645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01867645, "The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01867645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*